Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…